Valuation: GlucoTrack, Inc.

Market Cap 2.25M 1.97M 1.82M 1.68M 3.2M 214M 3.25M 21.79M 8.47M 106M 8.46M 8.28M 365M P/E 2024 *
-
P/E 2025 -0.12x
Enterprise Value -1.68M -1.47M -1.36M -1.26M -2.39M -160M -2.43M -16.28M -6.33M -78.86M -6.32M -6.18M -273M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
99.07%
Yield 2024 *
-
Yield 2025 -
1 day+13.24%
1 week+12.85%
Current month+12.85%
1 month-40.59%
3 months-47.28%
6 months-90.95%
Current year-90.70%
1 week 0.3
Extreme 0.301
0.38
1 month 0.29
Extreme 0.2907
0.56
Current year 0.29
Extreme 0.2907
4.24
1 year 0.29
Extreme 0.2907
14.14
3 years 0.29
Extreme 0.2907
5,939.99
5 years 0.29
Extreme 0.2907
46,800.05
10 years 0.29
Extreme 0.2907
468,000.47
Manager TitleAgeSince
Chief Executive Officer 59 -
Director of Finance/CFO 66 2025-01-27
Chief Operating Officer - 2025-01-31
Director TitleAgeSince
Director/Board Member 59 2024-08-26
Director/Board Member 56 2023-08-24
Chairman 63 2024-02-12
Date Insider Type Main position Quantity % Market Cap.
25-03-25Free

Director

4,490 0.0431%
25-03-24Others

Chief Executive Officer

42 0.0004%
25-03-24Free

Director

8,747 0.0840%
Change 5-day change 1-year change 3-year change Capi.($)
+13.24%+12.85%-94.35%-99.98% 2.25M
-0.45%+4.73%+2.44%+8.88% 49.74B
+0.25%+1.70%+419.39%+621.71% 40.49B
-0.16%+8.42%+28.20%+63.00% 34.35B
+1.10%+7.77%+28.18%-3.96% 34.75B
+1.31%-0.56%+5.12%+33.90% 26.98B
-0.35%+0.09% - - 16.58B
-3.33%+3.15%+71.30%+131.94% 15.6B
+3.79%+8.88%+106.63%+106.63% 14.27B
-2.18%-1.61%+12.87%+18.30% 13.76B
Average +1.32%+3.98%+64.42%+97.82% 24.65B
Weighted average by Cap. +0.09%+4.59%+95.67%+140.85%

Financials

2024 2025
Net sales - -
Net income -22.6M -19.77M -18.22M -16.89M -32.07M -2.14B -32.58M -219M -84.98M -1.06B -84.84M -83M -3.66B -19.39M -16.97M -15.64M -14.49M -27.51M -1.84B -27.96M -187M -72.91M -908M -72.79M -71.21M -3.14B
Net Debt -5.35M -4.68M -4.31M -4M -7.59M -508M -7.71M -51.74M -20.12M -251M -20.09M -19.65M -866M -3.94M -3.45M -3.18M -2.94M -5.59M -374M -5.68M -38.07M -14.81M -184M -14.78M -14.46M -637M
Logo GlucoTrack, Inc.
Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
Employees
15
Date Price Change Volume
26-07-07 US$0.3600 +13.24% 10,379,539
26-07-06 US$0.3179 -0.66% 2,478,024
26-07-02 US$0.3200 -7.97% 74,274
26-07-01 US$0.3477 +9.00% 269,035
26-06-30 US$0.3190 +2.24% 111,137
  1. Stock Market
  2. Stocks
  3. GCTK Stock